Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Firelight Launches as First XRP Staking Platform on Flare, Introduces DeFi Cover Feature 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
Rio Tinto Raises 2025 Copper Output Outlook as Oyu Tolgoi Expansion Accelerates 
Gold Prices Steady as Markets Await Key U.S. Data and Expected Fed Rate Cut 
IKEA Expands U.S. Manufacturing Amid Rising Tariffs and Supply Chain Strategy Shift 
Dollar Slides to Five-Week Low as Asian Stocks Struggle and Markets Bet on Fed Rate Cut 
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Tesla Expands Affordable Model 3 Lineup in Europe to Boost EV Demand 
Michael Dell Pledges $6.25 Billion to Boost Children’s Investment Accounts Under Trump Initiative 
Spain’s Industrial Output Records Steady Growth in October Amid Revised September Figures 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
IMF Deputy Dan Katz Visits China as Key Economic Review Nears 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Abbott Nutrition said last weekend that it had reopened its Sturgis, Michigan plant to resume the production of baby formula. The company hopes that the nationwide shortage of milk will be addressed once it begins the normal production once again.
Abbott Nutrition was able to open its production facility in Michigan after the U.S. Food and Drug Administration (USFDA) had given it the go-ahead to do so. The permit was granted by the agency after the company met the initial requirements as part of a May 16 consent decree.
According to CNBC, Abbott Nutrition will now restart the production of its EleCare baby formula that has been formulated for children who have difficulties digesting other products. The company will also manufacture its other specialty milk and metabolic formulas for infants.
As the company is now able to begin production again, it is hoping to release the first batch of EleCare milk products by June 20. Currently, Abbott is still working to comply with the guidelines set for the resumption of production for its Similac milk line and other infant formulas.
“We understand the urgent need for formula and our top priority is getting high-quality, safe formula into the hands of families across America,” Abbott’s spokesman said in a statement. “We will ramp production as quickly as we can while meeting all requirements.“
It was noted that the issue with the supply of baby formula began in the early stage of the COVID-19 pandemic. However, the situation got worse when Abbott Nutrition’s production facility in Michigan was ordered to close due to contamination. The plant was shut down in February following reports of illnesses in babies after consuming the company-made milk formulas, and two infants have died.
“The FDA is continuing to work diligently to ensure the safe resumption of production of infant formula at Abbott Nutrition’s Sturgis, Michigan, facility,” the USFDA commented with regards to Abbot’s plant reopening. “The agency expects that the measures and steps it is taking, and the potential for Abbott Nutrition’s Sturgis, Michigan, facility, to safely resume production in the near-term, will mean more and more infant formula is either on the way to or already on store shelves moving forward.”
